Download PDF
Dtsch Med Wochenschr 2013; 138(40): 2041-2044
DOI: 10.1055/s-0033-1349506
Verdauungs- und Stoffwechselkrankheiten | Commentary
Gastroenterologie
© Georg Thieme Verlag KG Stuttgart · New York

Alkoholische Hepatitis

Alcohol-induced hepatitis
H. K. Seitz
1   Alkohol Forschungszentrum, Universität Heidelberg
2   Medizinische Klinik, Klinikum Salem, Heidelberg
,
F. Stickel
3   Abteilung für Hepatologie, Klinik Beau-Site, Bern
› Author Affiliations
Further Information

Publication History

Publication Date:
24 September 2013 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

Hepatitis - Alkohol - Prognose-Scores - N-Acetylcystein - Glukokortikoide

Keywords

Hepatitis - alcohol - prognostic scores - N-acetylcyteine
 

  • Literatur

  • 1 Affo S, Dominguez M, Lozano JJ et al. Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis. Gut 2013; 62: 452-460
    CrossrefPubMedGoogle Scholar
  • 2 European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012; 57: 399-420
    PubMedGoogle Scholar
  • 3 Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011; 141: 1572-1585
    CrossrefPubMedGoogle Scholar
  • 4 Louvet A, Naveau S, Abdelnour M et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007; 45: 1348-1354
    CrossrefPubMedGoogle Scholar
  • 5 Mathurin P, Moreno C, Samuel D et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011; 365: 1790-1800
    CrossrefPubMedGoogle Scholar
  • 6 Mathurin P, O'Grady J, Carithers RL et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011; 60: 255-260
    CrossrefPubMedGoogle Scholar
  • 7 Mueller S, Millonig G, Sarovska L et al. Increased liver stiffness in alcoholic liver disease: differentiating fibrosis from steatohepatitis. World J Gastroenterol 2010; 16: 966-972
    CrossrefPubMedGoogle Scholar
  • 8 Naveau S, Chollet-Martin S, Dharancy S et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004; 39: 1390-1397
    CrossrefPubMedGoogle Scholar
  • 9 Nguyen-Khac E, Thevenot T, Piquet MA et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med 2011; 365: 1781-1789
    CrossrefPubMedGoogle Scholar
  • 10 O'Shea RS, Dasarathy S, McCullough AJ. Practical Guideline Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology 2010; 51: 307-328
    CrossrefPubMedGoogle Scholar
  • 11 Parker R, Armstrong MJ, Corbett C et al. Pentoxifylline for the treatment of severe alcoholic hepatitis. Aliment Pharmacol Ther 2013; 37: 845-854
    CrossrefPubMedGoogle Scholar
  • 12 Plauth M, Cabre E, Riggio O et al. ESPEN Guidelines on Enteral Nutrition: Liver disease. Clin Nutr 2006; 25: 285-294
    CrossrefPubMedGoogle Scholar
  • 13 Rivera CA, Adegboyega P, van Rooijen N et al. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 2007; 47: 571-579
    CrossrefPubMedGoogle Scholar
  • 14 Stickel F, Hoehn B, Schuppan D et al. Nutritional therapy in alcoholic liver disease. Aliment Pharmacol Ther 2003; 18: 357-373
    CrossrefPubMedGoogle Scholar
  • 15 Stickel F, Seitz HK. Update on the management of alcoholic steatohepatitis. J Gastrointestin Liver Dis 2013; 22: 189-197
    PubMedGoogle Scholar